EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Michael T. McCabe, Heidi M. Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson, Glenn S. Van Aller, Yan Liu, Anthony Della Pietra, Louis V. LaFrance, Mark Mellinger, Celine Duquenne, Xinrong Tian, Ryan G. Kruger, Charles F. McHugh, William H. Miller, Dashyant Dhanak, Sharad K. Verma, Peter J. Tummino, Caretha L. Creasy, Alan P. GravesElsie Diaz

Research output: Contribution to journalLetterpeer-review

1155 Scopus citations


In eukaryotes, post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27). EZH2 overexpression is implicated in tumorigenesis and correlates with poor prognosis in several tumour types. Additionally, somatic heterozygous mutations of Y641 and A677 residues within the catalytic SET domain of EZH2 occur in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The Y641 residue is the most frequently mutated residue, with up to 22% of germinal centre B-cell DLBCL and follicular lymphoma harbouring mutations at this site. These lymphomas have increased H3K27 tri-methylation (H3K27me3) owing to altered substrate preferences of the mutant enzymes. However, it is unknown whether specific, direct inhibition of EZH2 methyltransferase activity will be effective in treating EZH2 mutant lymphomas. Here we demonstrate that GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma.

Original languageEnglish (US)
Pages (from-to)108-112
Number of pages5
Issue number7427
StatePublished - Dec 6 2012
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations'. Together they form a unique fingerprint.

Cite this